COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

Emerging SARS-CoV-2 Mutations: Impact on Thermo Fisher Scientific Assay Performance

ThermoFisher-DarkDaily-Webinar
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Dark Daily and COVID-19 STAT Intelligence Briefings is offering this FREE webinar as a service to our clinical lab and pathology colleagues

ThermoFisher logo

FREE Webinar

Recorded March 24, 2021

Stream Webinar Now

SARS-CoV-2 has been mutating at a rate of about one to two mutations per month. The Centers for Disease Control and Prevention (CDC) reports that multiple variants of the virus are now circulating globally, including P.1 (Brazil), B.1.351 (South Africa), and B.1.1.7 (United Kingdom). What makes the new B.1.1.7. UK variant different is that it seems to have acquired mutations much more quickly than scientists expected, resulting in a reported 70% increase in transmissibility.

The emergence of multiple SARS-CoV-2 variants brings fast-moving questions for clinical laboratory administrators about the ability to identify new potential coronavirus SARS-CoV-2 variants. One of the most notable is how standard COVID-19 testing can be positioned to detect these new variants, particularly now that the S-gene dropout issue has been discovered.

During this complimentary webinar with follow-up Q&A, you will hear about the important clinical implications (epidemiological, prognostic, and predictive) of these “variants of concern,” the importance of early detection of these variants, and the steps your lab can take to confidently detect the COVID-19 virus with a very high degree of specificity and sensitivity, and identify the S-gene dropout.

Attend this 60-minute program, and you will:

  • Get key insights into the novel SARS-CoV-2 strains including the UK variant (B.1.1.7) and the South African variant (B.1.351/501Y.V2) and the significant mutations associated with these variants
  • Understand automation and miniaturization of clinical SARS-CoV-2 RT-qPCR testing for population genomic surveillance
  • Learn how the TaqPath workflow addresses the S-gene dropout issue by detecting this unique variant
  • Discover how the mutations in these “variants of concern” are relevant to the different TaqPath COVID-19 assays
  • Be briefed on how UCSD and Scripps are collaborating to deliver rapid and cost-effective genomic epidemiology to public health officials, and much more

Stream Now

Who should attend?

  • Clinical laboratory directors
  • Laboratory managers
  • Clinical pathologists
  • Laboratory technicians
  • Anyone involved in clinical laboratory testing

With your attendance of this webinar:

  • Learn about how your clinical laboratory can best serve the senior care segment
  • Gain insights into the most effective and efficient ways to connect to and support long-term care customers
  • Find out what your lab should look for in an integration partner
  • Hear new ways to grow and retain your lab business

Due to the threat of enhanced transmissibility, SARS-CoV-2 viral mutations are such a concern that the US Food and Drug Administration (FDA) issued an alert to clinical laboratory staff and healthcare providers that variants may potentially impact SARS-CoV-2 molecular tests, and is taking action to ensure authorized COVID-19 diagnostic tests remain accurate.

Attend this important webinar and learn what your lab needs to know now.

Stream Now

 Sponsored by:

ThermoFisher logo

 

 

 

 

More COVID-19 Coverage Can Be Found in THE DARK REPORT

COVID-19 TESTING DATA